JP2013509435A5 - - Google Patents

Download PDF

Info

Publication number
JP2013509435A5
JP2013509435A5 JP2012537131A JP2012537131A JP2013509435A5 JP 2013509435 A5 JP2013509435 A5 JP 2013509435A5 JP 2012537131 A JP2012537131 A JP 2012537131A JP 2012537131 A JP2012537131 A JP 2012537131A JP 2013509435 A5 JP2013509435 A5 JP 2013509435A5
Authority
JP
Japan
Prior art keywords
patient
injectable
depot
dose
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012537131A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013509435A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/054807 external-priority patent/WO2011053829A1/en
Publication of JP2013509435A publication Critical patent/JP2013509435A/ja
Publication of JP2013509435A5 publication Critical patent/JP2013509435A5/ja
Pending legal-status Critical Current

Links

JP2012537131A 2009-10-30 2010-10-29 長時間作用型注入可能パリペリドンエステルに関連した投与レジメン Pending JP2013509435A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25669609P 2009-10-30 2009-10-30
US61/256,696 2009-10-30
PCT/US2010/054807 WO2011053829A1 (en) 2009-10-30 2010-10-29 Dosing regimen associated with long-acting injectable paliperidone esters

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015237117A Division JP2016102123A (ja) 2009-10-30 2015-12-04 長時間作用型注入可能パリペリドンエステルに関連した投与レジメン

Publications (2)

Publication Number Publication Date
JP2013509435A JP2013509435A (ja) 2013-03-14
JP2013509435A5 true JP2013509435A5 (enExample) 2013-12-19

Family

ID=43302985

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012537131A Pending JP2013509435A (ja) 2009-10-30 2010-10-29 長時間作用型注入可能パリペリドンエステルに関連した投与レジメン
JP2015237117A Pending JP2016102123A (ja) 2009-10-30 2015-12-04 長時間作用型注入可能パリペリドンエステルに関連した投与レジメン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015237117A Pending JP2016102123A (ja) 2009-10-30 2015-12-04 長時間作用型注入可能パリペリドンエステルに関連した投与レジメン

Country Status (12)

Country Link
US (2) US20110105536A1 (enExample)
EP (1) EP2493473A1 (enExample)
JP (2) JP2013509435A (enExample)
KR (1) KR20120116401A (enExample)
CN (1) CN102802631A (enExample)
AU (2) AU2010313290A1 (enExample)
BR (1) BR112012010195A2 (enExample)
CA (1) CA2742393A1 (enExample)
CL (1) CL2012001110A1 (enExample)
MX (1) MX2012005083A (enExample)
NZ (1) NZ599558A (enExample)
WO (1) WO2011053829A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
CA2655335C (en) 2007-12-19 2016-09-06 Janssen Pharmaceutica N.V. Prolonged-release injectable suspensions of paliperidone palmitate, and dosage forms and delivery systems incorporating same
EP2547206B1 (en) 2010-03-15 2016-05-11 Inventia Healthcare Private Limited Stabilized prolonged release pharmaceutical composition comprising atypical antipsychotic
ES2972387T3 (es) 2011-03-18 2024-06-12 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden ésteres de sorbitán
CN102993200B (zh) * 2011-09-10 2016-02-03 鲁翠涛 帕潘立酮氨基酸酯及其制备方法
US9999670B2 (en) 2012-03-19 2018-06-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
WO2013142202A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising glycerol esters
CA2867121C (en) 2012-03-19 2021-05-25 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
JP6654042B2 (ja) 2012-09-19 2020-02-26 アルカームス ファーマ アイルランド リミテッド 貯蔵安定性が改善された医薬組成物
AU2015231278B2 (en) 2014-03-20 2020-01-23 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
DK3744326T3 (da) * 2015-04-07 2024-02-05 Janssen Pharmaceutica Nv Doseringsregime for glemte doser til langtidsvirkende injicerbare paliperidonestere
ITUB20155193A1 (it) * 2015-11-03 2017-05-03 Italfarmaco Spa Sospensioni orali di Givinostat fisicamente e chimicamente stabili
AU2019230014B2 (en) 2018-03-05 2024-11-28 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN114728134A (zh) 2019-09-25 2022-07-08 杨森制药公司 药物施用系统的互连
WO2022049006A1 (en) * 2020-09-02 2022-03-10 Janssen Pharmaceutica Nv Pre-filled syringe with optimized stopper placement
EP4025188B1 (en) * 2020-11-30 2024-01-10 Janssen Pharmaceutica NV Dosing regimens associated with extended release paliperidone injectable formulations
SI4025187T1 (sl) 2020-11-30 2024-03-29 Janssen Pharmaceutica Nv Režimi odmerjanja, povezani s formulacijami paliperidona za injiciranje s podaljšanim sproščanjem
CN116528836A (zh) 2020-11-30 2023-08-01 詹森药业有限公司 与延长释放帕潘立酮可注射制剂相关的给药方案
US20240148641A1 (en) * 2021-03-17 2024-05-09 Medincell S.A. Long Acting Injectable Formulation Comprising Risperidone and Biodegradable Polymers
MX2024002215A (es) 2021-08-20 2024-05-10 Janssen Pharmaceutica Nv Regímenes de dosificación asociados con formulaciones inyectables de paliperidona de liberación prolongada.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254556A (en) 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
TW487572B (en) 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
KR100338776B1 (ko) 2000-07-11 2002-05-31 윤종용 멀티 로우 어드레스 테스트 가능한 반도체 메모리 장치 및그 테스트 방법
CN101163702B (zh) 2005-04-25 2011-09-07 詹森药业有限公司 制备无菌的3-[2-[4-(6-氟-1,2-苯并异唑-3-基)-1-哌啶基]乙基]-6,7,8,9-四氢-9-羟基-2-甲基-4H-吡啶并[1,2-a]嘧啶-4-酮棕榈酸酯的方法
US20070197591A1 (en) * 2005-12-12 2007-08-23 Sandra Boom Use of paliperidone for the treatment of a mental disorder in a psychiatric patient with reduced hepatic function
JP2009524685A (ja) * 2006-08-14 2009-07-02 テバ ファーマシューティカル インダストリーズ リミティド 9−ヒドロキシ−リスペリドン(パリペリドン)の結晶型
CA2655335C (en) 2007-12-19 2016-09-06 Janssen Pharmaceutica N.V. Prolonged-release injectable suspensions of paliperidone palmitate, and dosage forms and delivery systems incorporating same

Similar Documents

Publication Publication Date Title
NZ599558A (en) Dosing regimen associated with long-acting injectable paliperidone esters
IL309340A (en) Dosing regimen for missing doses of paliperidone long-acting injectable esters
Lara et al. Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression
JP2015187125A5 (enExample)
JP2014114288A5 (enExample)
JP2017031213A5 (enExample)
JP2018510894A5 (enExample)
JP2015512392A5 (enExample)
RU2008138381A (ru) Режимы дозирования адреналина
JP2011511072A5 (enExample)
JP2019196370A5 (enExample)
IL273976B1 (en) Methods and materials for nt-3 gene therapy
JP2016514132A5 (enExample)
SI2523688T1 (en) Formulation of antibodies and therapeutic regimes
JP2017538705A5 (enExample)
JP2013543501A5 (enExample)
FI3998078T3 (fi) Annoksensuurentamisentsyymikorvaushoito happaman sfingomyelinaasin puutoksen hoitamista varten
JP2012193216A5 (enExample)
IL318548A (en) Methods for treating muscular dystrophy with casimersen
FI4119569T3 (fi) Konjugoituja antisense-yhdisteitä käytettäviksi hoidossa
JP2019511506A5 (enExample)
JP2018531605A5 (enExample)
RU2019107146A (ru) Схемы и способы лечения рассеянного склероза с применением офатумумаба
JP2023520004A5 (enExample)
Gopalakrishna et al. Long-acting injectable aripiprazole: how might it fit in our tool box?